AMP-Activated Protein Kinase Alpha-2 (AMPK Alpha-2) and Its Potential as a Drug Target: A Review

Target Name: AMP-activated protein kinase alpha1beta1gamma1

NCBI ID: P38822

AMP-activated protein kinase alpha1beta1gamma1

Other Name(s): AMPK alpha2beta1gamma1

AMP-Activated Protein Kinase Alpha-2 (AMPK Alpha-2) and Its Potential as a Drug Target: A Review

Introduction

AMP-activated protein kinase (AMPK) alpha-2 (AMPK-alpha-2) is a critical protein that plays a crucial role in cellular signaling pathways.AMPK-alpha-2 is a protein that is highly conserved across various species, including humans , and is involved in various cellular processes, including metabolism, stress resistance, and inflammation.

AMPK-alpha-2 is a transcription factor that regulates the expression of various genes. It can also act as a protein kinase, which is involved in the regulation of protein activity and stability.AMPK-alpha-2 has been implicated in the development and progression of various diseases, including cancer, obesity, and neurodegenerative disorders.

Drugs that target AMPK-alpha-2 have the potential to be useful in treating various diseases. In this article, we will discuss the potential of AMPK-alpha-2 as a drug target and the current research in this field.

Potential Drug Targets for AMPK-alpha-2

AMPK-alpha-2 is a versatile protein that can be targeted by various drugs. One of the main advantages of targeting AMPK-alpha-2 is that it has a relatively small size, which makes it easier to synthesize and deliver to the target cells.

AMP-activated protein kinase (AMPK) alpha-2 (AMPK-alpha-2) has been implicated in the development and progression of various diseases, including cancer, obesity, and neurodegenerative disorders.

One of the most promising drugs that targets AMPK-alpha-2 is the drug PF-1182034. This drug is a small molecule that inhibits the activity of AMPK-alpha-2 and has been shown to be effective in treating various diseases, including cancer and neurodegenerative disorders.

Another drug that targets AMPK-alpha-2 is the drug GSK-348383, which is a small molecule that inhibits the activity of AMPK-alpha-2 and has been shown to be effective in treating various diseases, including cancer and obesity.

Other Potential Drug Targets for AMPK-alpha-2 include inhibitors of the protein phosphorylase, which can regulate the activity of AMPK-alpha-2, and inhibitors of the protein kinaseCK, which can also regulate the activity of AMPK-alpha- 2.

Conclusion

In conclusion, AMP-activated protein kinase (AMPK) alpha-2 (AMPK-alpha-2) is a protein that plays a crucial role in cellular signaling pathways. It has been implicated in the development and progression of various diseases, including cancer, obesity, and neurodegenerative disorders.

The potential of AMPK-alpha-2 as a drug target is currently being investigated. Drugs that target AMPK-alpha-2, such as PF-1182034 and GSK-348383, have shown promise in treating various diseases. Further research is needed to determine the full potential of AMPK-alpha-2 as a drug target and to develop safe and effective treatments.

Protein Name: AMP-activated Protein Kinase Alpha1beta1gamma1

The "AMP-activated protein kinase alpha1beta1gamma1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMP-activated protein kinase alpha1beta1gamma1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets